Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07462143) titled 'A Phase ?/? Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer' on March 4.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: RemeGen Co., Ltd.
Condition:
Colorectal (Colon or Rectal) Cancer
Intervention:
Drug: RC148 (Dose 1) plus Capecitabine and Oxaliplatin
Recruitment Status: Not recruiting
Phase: Phase 2/Phase 3
Date of First Enrollment: April 30, 2026
Target Sample Size: 700
Countries of Recruitment:
China
To know m...